Moreover, drugs acting as PTP1B inhibitors could enhance the endogenous activity of LMO4, a natural PTP1B inhibitor, but could also treat the symptoms of T2DM, a condition often associated with MDD. This evidence concerns the gene PTPN1 and type 2 diabetes mellitus.